Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in human safety study of FX-322 in adults undergoing cochlear implantation.

Next Previous
X
Search
Trial Profile

First in human safety study of FX-322 in adults undergoing cochlear implantation.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FX 322 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Frequency Therapeutics

    • Most Recent Events

    • 21 Dec 2017 Primary endpoint has been met. (To assess diffusion of FX-322 from the middle ear, across the oval and round window membranes, and into the cochlear fluid (perilymph). The concentration of FX-322 will be analysed from the perilymph fluid and blood plasma by standard laboratory methods.), as reported in a Frequency Therapeutics Media Release.
    • 21 Dec 2017 Results published in the Frequency Therapeutics Media Release
    • 21 Dec 2017 Status changed from recruiting to completed, as reported in a Frequency Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top